Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 9, 2010, Pages 1758-1765

  Braun, Nicole A ^a   Mendez Fernandez, Yanice V ^a   Covarrubias, Roman ^a   Porcelli, Steven A ^b   Savage, Paul B ^c   Yagita, Hideo ^d   Van Kaer, Luc ^e   Major, Amy S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Brigham Young University   (United States)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antigen; hypercholesterolemia; immunology; lipid; lymphocytes

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CD69 ANTIGEN; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; ALPHA-GALACTOSYLCERAMIDE; APOPTOSIS REGULATORY PROTEIN; CYTOKINE; GALACTOSYLCERAMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY A; PDCD1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL EXPANSION; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DYSLIPIDEMIA; IN VIVO STUDY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CHRONIC DISEASE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HYPERLIPIDEMIA; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; NATURAL KILLER T CELL; TIME;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, SURFACE; APOLIPOPROTEINS E; APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CHRONIC DISEASE; CLONAL ANERGY; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GALACTOSYLCERAMIDES; HYPERLIPIDEMIAS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY A; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; TIME FACTORS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 77955984247     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.206045     Document Type: Article

References (43)

1. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol. 1997; 15:535-562.
2. Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, Unutmaz D, Van Kaer L, Joyce S. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol. 2005;174:4696-4705.
3. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol. 2002;2:557-568.
4. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by a-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003;198:267-279.
5. Roelofs-Haarhuis K, Wu X, Nowak M, Fang M, Artik S, Gleichmann E. Infectious nickel tolerance: a reciprocal interplay of tolerogenic APCs and T suppressor cells that is driven by immunization. J Immunol. 2003;171:2863-2872.
6. Wilson MT, Singh AK, Van Kaer L. Immunotherapy with ligands of natural killer T cells. Trends Mol Med. 2002;8:225-231.
7. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med. 2001;194: 313-320.
8. Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med. 2001;194:1801-1811.
9. Major AS, Wilson MT, McCaleb JL, Ru Su Y, Stanic AK, Joyce S, Van Kaer L, Fazio S, Linton MF. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arte-rioscler Thromb Vasc Biol. 2004;24:2351-2357.
10. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, Berne GP. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med. 2004;199:417-422.
11. Nakai Y, Iwabuchi K, Fujii S, Ishimori N, Dashtsoodol N, Watano K, Mishima T, Iwabuchi C, Tanaka S, Bezbradica JS, Nakayama T, Tan-iguchi M, Miyake S, Yamamura T, Kitabatake A, Joyce S, Van Kaer L, Onoe K. Natural killer T cells accelerate atherogenesis in mice. Blood. 2004;104:2051-2059.
12. Van DerLaan PA, Reardon CA, Sagiv Y, Blachowicz L, Lukens J, Nis-senbaum M, Wang CR, Getz GS. Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am J Pathol. 2007;170:1100-1107.
13. Wu L, Gabriel CL, Parekh VV, Van Kaer L. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens. 2009;73:535-545.
14. Kim S, Lalani S, Parekh VV, Vincent TL, Wu L, Van Kaer L. Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice. J Clin Invest. 2008;118:2301-2315.
15. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest. 2005;115:2572-2583.
16. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92.
17. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA. 2000;97:5498-5503.
18. -/-) mice. Lupus. 2008;17:1070-1078.
19. Van Den Elzen P, Garg S, Leon L, Brigl M, Leadbetter EA, Gumperz JE, Dascher CC, Cheng TY, Sacks FM, Illarionov PA, Besra GS, Kent SC, Moody DB, Brenner MB. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature. 2005;437:906-910.
20. Yu KO, Im JS, Illarionov PA, Ndonye RM, Howell AR, Besra GS, Porcelli SA. Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand a-galactosylceramide bound to mouse CD1d. J Immunol Methods. 2007;323:11-23.
21. Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang C-R, Joyce S, Van Kaer L. The response of natural killer T cells to glycolipid antigens in characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA. 2003;19:10913-10918.
22. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008;45:963-970.
23. Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M, Yagita H, Kang CY. Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol. 2008;181:6707-6710.
24. Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, Kumar V, Wu L, Kaer LV. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol. 2009;182:2816-2826.
25. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci. 2008;99:638-645.
26. Fletcher MT, Baxter AG. Clinical application of NKT cell biology in type I (autoimmune) diabetes mellitus. Immunol Cell Biol. 2009;87:315-323.
27. Li D, Xu XN. NKT cells in HIV-1 infection. Cell Res. 2008;18:817-822.
28. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol. 2009;9:28-38.
29. Zhou D, Mattner J, Cantu C III, Schrantz N, Yin N, Gao Y, Sagiv Y, Hudspeth K, Wu YP, Yamashita T, Teneberg S, Wang D, Proia RL, Levery SB, Savage PB, Teyton L, Bendelac A. Lysosomal glycosphin-golipid recognition by NKT cells. Science. 2004;306:1786-1789.
30. Sagiv Y, Hudspeth K, Mattner J, Schrantz N, Stern RK, Zhou D, Savage PB, Teyton L, Bendelac A. Cutting edge: impaired glycosphingolipid trafficking and NKT cell development in mice lacking Niemann-Pick type C1 protein. J Immunol. 2006;177:26-30.
31. Schrantz N, Sagiv Y, Liu Y, Savage PB, Bendelac A, Teyton L. The Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells. J Exp Med. 2007;204:841-852.
32. Schumann J, Facciotti F, Panza L, Michieletti M, Compostella F, Collmann A, Mori L, De Libero G. Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism. Eur J Immunol. 2007;37:1431-1441.
33. Gadola SD, Silk JD, Jeans A, Illarionov PA, Salio M, Besra GS, Dwek R, Butters TD, Platt FM, Cerundolo V. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp Med. 2006;203:2293-2303.
34. Allan LL, Hoefl K, Zheng DJ, Chung BK, Kozak FK, Tan R, Van Den Elzen P. Apolipoprotein mediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells. Blood. 2009.
35. Garner B, Priestman DA, Stocker R, Harvey DJ, Butters TD, Platt FM. Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. J Lipid Res. 2002;43:205-214.
36. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med. 2003;198:173-181.
37. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol. 2003;4:1230-1237.
38. Bai L, Sagiv Y, Liu Y, Freigang S, Yu KO, Teyton L, Porcelli SA, Savage PB, Bendelac A. Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen aGalCer. Proc Natl Acad Sci USA. 2009;106:10254-10259.
39. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subra-maniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007; 27:670-684.
40. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350-354.
41. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, Sekaly RP. Upregulation of PD-1 expression on HIV-specific CD8 + T cells leads to reversible immune dysfunction. Nat Med. 2006;12: 1198-1202.
42. Weatherill AR, Lee JY, Zhao L, Lemay DG, Youn HS, Hwang DH. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol. 2005;174:5390-5397.
43. Van Kaer L. NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol. 2007;19:354-364.